Fibre in pediatric metabolic dysfunction associated steatotic liver disease (MASLD)
Paige Cheveldayoff, MSc Candidate & Research Coordinator
Supervisors:
Dr. Nik Pai, Associate Clinical Professor, Pediatrics, McMaster University (Research Coordinator Supervisor)
Dr. Katherine Morrison, Professor, Pediatrics, McMaster University (MSc Supervisor)
Metabolic dysfunction associated steatotic liver disease (MASLD) is projected to become one of the leading causes of liver transplantation over the next 5 years, overtaking alcoholic liver disease and viral hepatitis. Soluble fibres have been shown to decrease hepatic fat content in adults and animal models, but the research has yet to be done in children. The FIND study is a 6 month, double blind, randomized controlled trial, that aims to examine the efficacy of soluble fibre supplementation on the treatment of pediatric MASLD.
Learning Objectives:
1. Understand the development of MASLD in a pediatric population.
2. To begin to examine the effectiveness of a soluble fibre for the treatment of pediatric MASLD.
macpedsrrt.ca 